Clinical trials: Resistant Depression, Treatment
Treatment Resistant Bipolar Depression
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression
This study is testing a new oral ketamine treatment called KET-AD in adults with treatment-resistant bipolar depression (TRBD). The study will look at how safe and tolerable the treatment is, and whether it may help improve…
- Trial name
- NCT07644767
- Testing
- KET-AD
- Volunteers
- 160 people
- Sponsor
- Neurocentrx Pharma Pty Ltd
Major Depressive Disorder
Inflammation and Electroconvulsive Therapy
The purpose of this study is to explore whether electroconvulsive therapy (ECT) accidentally leads to a side effect of brain inflammation.
- Trial name
- NCT02095639
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Centre for Addiction and Mental Health
Moderate Depression, Major Depressive Disorder
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.
- Conditions
- Moderate Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT06112652
- Testing
- 4 session rTMS, 6 session rTMS, 8 session rTMS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changping Laboratory
Treatment-resistant Depression (TRD)
Auditory MMN EEG in TRD in Response to Ketamine
To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.
- Trial name
- NCT05464264
- Testing
- Ketamine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine
Depressive Disorder, Major
Ketamine for Treatment Resistant MDD
This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IM/SC ketamine for treatment resistant MDD.
- Trial name
- NCT04021433
- Testing
- Ketamine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Bipolar Depression
Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression
The aim of this randomized, single-blind trial is to evaluate the effectiveness and tolerability of high frequency or low frequency repetitive transcranial magnetic stimulation (rTMS) in patients with resistant bipolar…
- Trial name
- NCT01586793
- Testing
- Magstim Rapid2 Stimulator
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Douglas Mental Health University Institute
Treatment Resistant Depression
Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)
The researchers are trying to test the feasibility and acceptability of using transcranial Direct Current Stimulation (tDCS) in hospitalized adult patients with Treatment Resistant Depression (TRD), assess for any preliminary…
- Trial name
- NCT06236711
- Testing
- tDCS
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder (MDD)
Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial
Transcranial magnetic stimulation(TMS) is a non-invasive form of brain stimulation that is cleared by the United States Food and Drug Administration (FDA) for depression.
- Trial name
- NNS (NCT07043738)
- Testing
- Transcranial Magnetic Stimulation
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Treatment Resistant Depression, Chronic Pain
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- TRANSCEND (NCT06518720)
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Accelerated rTMS for Treatment-Resistant Major Depression
High frequency repetitive transcranial magnetic stimulation (HF-rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks.
- Trial name
- NCT02125799
- Testing
- Accelerated HF-rTMS (Magstim Rapid 2 stimulator)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Douglas Mental Health University Institute
Treatment Resistant Depression, Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine
- Trial name
- NCT05615948
- Testing
- VTS-K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Theresa Jacob, PhD, MPH
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Pharmacogenomics for Antidepressant Guidance and Education
More than one out of three individuals treated for major depressive disorder (MDD) do not experience a full reduction of symptoms even when treated with adequate antidepressant medication.
- Trial name
- NCT01555021
- Testing
- Genotyping assays
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Depressed Mood
ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings.
- Trial name
- ATLAS-1 (NCT07528014)
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Salma Health, Inc.
Depressive Disorder, Treatment-Resistant
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory…
- Trial name
- NCT02610712
- Testing
- Ketamine
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurology and Neurosurgery, Mexico
Treatment Resistant Depression
Efficacy of Deep Brain Stimulation(DBS) for Treatment-Resistant Depression(TRD)
The primary purpose of this study is to investigate the effect of deep brain stimulation (DBS) implantation in patients with Treatment-resistant Depression (TRD) targeting the ventral capsule/ventral striatum (VC/VS), Brodmann…
- Trial name
- DBS for TRD (NCT06542900)
- Testing
- Deep Brain Stimulation (DBS)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xuanwu Hospital, Beijing
Depression
rTMS in Treatment Resistant Depression
The purpose of this study is to determine the safety and efficacy of rTMS as an alternative treatment to ECT. The study will also provide data for a power analysis to support a larger clinical trial if there is evidence of a…
- Trial name
- rTMSECT (NCT02080507)
- Testing
- Active Neuronetics rTMS stimulator, Inactive Neuronetics rTMS stimulator
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Treatment Resistant Major Depressive Disorder
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).
- Trial name
- STRIDE-1 (NCT02741791)
- Testing
- AXS-05, Bupropion
- Where
- 74 sites in United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.